Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Cross screening panel
Assay data:1 Tested
SummaryRelated BioAssays by Target
Safety47 Scan (DiscoverX - Eurofins)
Calcium Channel L-Type, Dihydropyridine Eurofins Panlabs panel
Calcium Channel L-Type, Benzothiazepine Eurofins Panlabs panel
CA+/DHPSI/R Eurofins SafetyScreen44 (BI)
Compound was evaluated for inhibition of human CACNA1C in an in vitro cell-based assay measured by IonWorks automated patch clamp
Assay data:14 Active, 3 Activity ≤ 1 µM, 116 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Compound was evaluated for inhibition of rat Cacna1c in an in vitro assay with cellular components measured by membrane filtration
Assay data:31 Active, 1 Activity ≤ 1 nM, 14 Activity ≤ 1 µM, 943 Tested
Inhibition of Cav1.2 channel (unknown origin) upto 10000 nM
SummaryPubMed CitationRelated BioAssays by Target
Displacement of [3H]D 888 from rat brain L-type calcium channel verapamil binding site at 10 uM after 120 mins by scintillation counting analysis relative to control
Assay data:3 Tested
Inhibition of Cav1.2 (unknown origin) at 10 uM
Inhibition of recombinant human Cav1.2
Assay data:4 Tested
Inhibition of Cav1.2 (unknown origin) at 50 uM relative to control
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on